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Abstract  
The ideal temporary implant should offer enough mechanical support to allow healing 
of the fracture and then biodegrade and be resorbed by metabolic mechanisms without 
causing any toxic effect. The aim of this research has been to simultaneously study in 
situ bone healing and the biodegradation of AZ31 Mg alloy as an osteosynthesis 
material. The in vivo study was carried out in AZ31 implants with and without Mg-
fluoride coating inserted in un-fractured and fractured femurs of Wistar rats for long 
experimentation time, from 1 to 13 months, by means of computed tomography, 
histological and histomorphometric analysis. Tomography analysis showed the bone 
healing and biodegradation of AZ31 implants. The fracture is healed in 100% of the 
animals, and AZ31 maintains its mechanical integrity throughout the healing process. 
Biodegradation was monitored, quantifying the evolution of gas over time by 3D 
composition of tomography images. In all the studied groups, gas pockets disappear 
with time as a result of the diffusion process through soft tissues. Histomorphometric 
studies reveal that after 13 months the 46.32 % of AZ31 alloy has been resorbed. The 
resorption of the coated and uncoated AZ31 implants inserted in fractured femurs after 
1, 9 and 13 month has not statistically significant differences. There is a balance 
between the biodegradation of AZ31 and bone healing which allows the use of AZ31 to 
be proposed as an osteosynthesis material. 
 1. Introduction 
Metallic implants are commonly used in osteosynthesis due to their appropriate mechanical 
properties and biocompatibility [1]. The biodegradability and resorbability of magnesium makes 
it a particularly attractive material for medical use in fields such as endovascular surgery [2] and 
fracture osteosynthesis [3]. Magnesium has a similar Young's modulus to bone, which is an 
impediment to stress shielding phenomena [4], and also promotes bone formation [5].  
However, Mg presents a fast biodegradation rate, which in chloride-containing physiological 
media is accompanied by abundant gas formation [6-7]. The evolution of gas is an important 
factor as it can alter bone remodelling processes. 
One of the current issues in any type of fracture osteosynthesis is whether or not the implant 
needs to be removed once the damage has been repaired. The ideal temporary implant should 
provide sufficient mechanical support to allow the fracture to heal, and once this has been 
consolidated should then biodegrade and be resorbed and expelled by conventional metabolic 
mechanisms without causing any toxic effect on the organism [8, 9]. In the last few years Mg 
and its alloys have been proposed as appropriate implant materials in preference to polymeric 
materials, which are also biodegradable but afford less strain resistance and poorer mechanical 
properties [10]. The properties of Mg that make it suitable for endoprosthesic replacements are 
its low density of 1.4 g/cm
3
, its Young's modulus of 40-45 GPa close to that of bone (10-40 
GPa), its biocompatibility [11], biodegradability, and its ability to be resorbed without causing 
local or systemic toxic effects [8,9]. 
Different alternatives have been proposed to reduce the fast Mg corrosion rate and improve its 
mechanical properties, such as the development of new processes to achieve a suitable grain 
size [12-14], alloying with other materials [7, 15], or the performance of surface modification 
treatments [16-19]. In the latter case, chemical conversion treatments in hydrofluoric acid have 
proven to reduce the corrosion susceptibility of Mg and its alloys by generating an inert Mg 
fluoride layer on the metal surface [20, 21]. 
 The object of this research has been to simultaneously study in situ bone healing and the 
biodegradation of AZ31 Mg alloy as an osteosynthesis material in rat femurs. The variables 
studied have been the alloy's biocompatibility in healthy and broken bone, its biodegradation 
rate with time, and the influence of surface treatment. The conversion treatment was only 
studied in fractured bones, considering the real application in the clinical practice. The 
protection of the coating can exert a clearer influence when the biodegradation process is more 
favoured as it is the case of larger electrolyte volumes bathing the implant (bone fracture). This 
is one of the few studies in which a fracture model such as can be found in clinical practice has 
been performed.  
2. Materials and methods 
2.1. Sample preparation 
The AZ31 alloy was received from Magnesium Elektron Ltd. in the form of a rolled 3 mm thick 
sheet in O-temper condition (annealed at 345°C). The chemical composition of the AZ31 alloy 
was determined by wavelength dispersion X-ray fluorescence (WDXRF) to be: 3.37 ± 0.09 
wt.% Al, 0.78 ± 0.04 wt.% Zn, 0.22 ± 0.01 wt.% Mn (balance Mg). AZ31 was machined to 
form cylinders of 20 mm in length and 1 mm in diameter, with an average weight of 28.0 ± 0.3 
mg. The cylindrical specimens were rounded at both ends in order to eliminate sharp edges, to 
facilitate their insertion in the laboratory animals, and to avoid edge effects on the degradation 
rate. Prior to their insertion the surface of the pins was ground with SiC abrasive papers and 
finally polished with 1 m diamond suspension. Finally, the AZ31 pins were rinsed 
ultrasonically in ethanol. 
To reduce the biodegradation rate of AZ31 implants, half of the pins were subjected to a 
chemical conversion treatment applied by immersion of the pins in 48 wt.% HF solution at 
room temperature for 24 hours, followed by rinsing with deionised water and drying in a stream 
of warm air. This treatment gave rise to the magnesium fluoride (MgF2) protective layer [20].  
 Samples were gamma-ray sterilised prior implantation. 
2.2. Surgery  
 36 female Wistar rats of three months of age and approximately 200 g body weight (bw) were 
used. The animals were treated in accordance with European Union Guidelines for Ethical Care 
of Animals (86/609CEE) and Spanish regulations (RD 1201/2005). 
 The rats were randomly divided into four different groups of nine animals each. All the animals 
belonging to Groups 1 to 4 underwent surgical implantation of one single AZ31 alloy pin in its 
left hind leg. The animals in Groups 1 and 2 (no fractured femur) were fitted with an 
intramedullary pin (see protocol 1 below), while the animals belonging to Groups 3 and 4 (with 
fractured femur) underwent intramedullary pinning (see protocol 2 below). The pins implanted 
in groups 1 and 3 were previously subjected to surface modification with HF treatment, while 
the pins implanted in groups 2 and 4 remained untreated. 
The devices were implanted in the femur under general anaesthesia following two different 
protocols: 
Protocol 1. Intramedullary pinning no fractured femur  
The rat was placed in supine position to facilitate an anteromedial approach to the knee. A 1.1 
mm hole was drilled with a surgical punch through the intercondylar notch into the femoral 
intramedullary space. The implant was then inserted into the intramedullary channel by 
retrograde insertion. 
Protocol 2. Intramedullary pinning fractured femur 
In a lateral approach to the rat's femur, a comminuted middle shaft fracture was made about 10 
mm from the joint line. To reproduce the physiological conditions of the fracture, a unicortical 
cut was made with a Gillies saw followed by manual breakage of the other cortex, adopting a 
comminute long oblique fracture pattern. The endomedullary pin was inserted into the distal 
 medullary channel and the fracture was reduced by threading the proximal bone fragment with 
the pin. 
Following the operation, each rat received a prophylactic dose of analgesics and antibiotics: 5 
mg Enrofloxacin (BAYTRIL
®
, 10 mg/kg) and Meloxicam (METACAM
®
, 2 mg/kg), both in a 
single dose via subcutaneous injection. All the animals were kept in the same conditions. 
2.3. Computed Tomography  studies 
Computed Tomography, (CT) is taken as a suitable image diagnosis method in view of its high 
resolution to evaluate the biodegradation of the material and to monitor bone healing [22]. 
Tomography offers an easy-to-interpret image that allows simple identification of the material's 
position and outline and the morphology of the bone. It also permits analysis of the volume of 
gas (from the dark shades present on the images) that is released as a result of the 
electrochemical biodegradation reaction: 
Mg + 2 H2O → Mg 
2+
 + 2 OH
- 
+ H2 (g)   (1) 
The pins implanted in the femurs were analysed in situ on a weekly basis by means of 
tomography in the rats euthanized after one month and on monthly bases in those euthanized 
after 9 and 13 months. To assure their immobilisation during scanning, the rats were 
anesthetised with 2% isofluorane and then placed on the scanner bed (Albira ARS PET/CT 
hybrid tomograph, Oncovision, Valencia, Spain). The parameters chosen for the performance of 
scanning were as follows: 600 projections per acquisition, a radiation intensity of 0.8 mA and a 
voltage of 45 kV. Prior to the tomography study a scout image was taken to assure the right 
position of the femur in the field of view (64 x 64 mm) of the scanner. After this, the 
tomography images were reconstructed using a filtered back projection algorithm. The final 
tridimensional images have a voxel size of 0.125 mm
3
 (512x512x512 pixels) and were saved in 
an analytical format for subsequent analysis. 
 The volumes were interactively segmented using ITK-SAP [23]. Each volume was segmented 
into gas and implant, and the volume of each structure was computed using the resolution 
information present in the DICOM header. 
2.4. Histological and histomorphometric analysis  
Upon completion of the scheduled monitoring times of 1, 9 and 13 months, the rats were 
euthanized by intraperitoneal injection of 0.4 mg sodium pentobarbital (Dolethal®) diluted in 
serum. 
The tissue response around the AZ31 implants was assessed by means of histological and 
histomorphometric analysis. The femurs with implants were extracted and fixed in 10% 
buffered pH 7 formaldehyde and dehydrated in grading hydroxylethylmetacrylate resin 
concentrations, as mentioned in Donath and Breuner's method [24]. The femurs were cut into 
blocks and then set in Technovit
®
 resin. The cutting and grinding of hard tissues was performed 
with an EXAKT sawing machine and grinding equipment (Leica Microsystems, Wetzlar, 
Germany). Five cross sections of about 50 µm thickness were obtained from each femur. Usual 
histological laboratory stains were used: toluidine blue with Weigert haematoxylin (Merck) and 
Masson's trichrome (Merck). Also a variation of blue toluidine (Merck) staining, which does 
not require prior removal of the resin, has been used. Samples have been stained with Weigert 
haematoxylin, washed in water and immersed in blue toluidine at pH 4. The prior use of 
haematoxylin enhances the blue toluidine effect, and cell nuclei appear very dark, almost black. 
The intercellular substance is clearly differentiated in several shades of blue, depending on the 
degree of maturity of the bone. The Masson's trichrome makes it possible to appreciate the 
uncalcified osteoid tissue (orange), the calcified mature bone tissue (green) and the cell nuclei 
(dark red).  
The stained cross sections of femurs with implants were studied with an optical microscope 
(Zeiss). The images were transferred to MIP 4 software (Digital Image Systems, SL, Barcelona) 
to carry out the histomorphometric analysis. This software identifies the initial area occupied by 
 the implant which is easily recognised by the circle of new tissue around it and highlights the 
remaining AZ31 alloy implant by colour density so the loss of implant in each section can be 
calculated. 
2.5. Statistics 
The data obtained in tomography experimentation were summarised as mean ± standard 
deviation (S.D.). T-tests or Mann-Whitney tests were used to compare two independent groups. 
ANOVA for repeated measures and pairwise comparison with Bonferroni correction were used 
to compare means at different time-points. p-Values ≤ 0.05 were considered as statistically 
significant. Statistical analysis was performed with Statgraphics Online. 
3. Results 
3.1. Effect of the femur fracture on the biodegradation rate 
3.1.1. Computed tomography 
 Fig. 1 shows representative tomography images after 1, 3, 5, 9 and 13 months for groups 3 and 
4 with fractured femur (Figs. 1a-e) and groups 1 and 2 with un-fractured femur (Figs. 1f-j), 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1. Computed tomography images of implanted AZ31 magnesium alloy after 1, 3, 5, 9 
and 13 months of evolution in Wistar rats, for groups 2 and 4, uncoated implants. From a- e) 
with fractured femurs, and from f- j) with un-fractured femurs.  
These images show the changes experienced by the implant, the gas produced as a consequence 
of its degradation, and the evolution of the bone between 1 and 13 months after implantation. 
Observation of the implants shows a well-defined outline in the images for 1 month in un-
fractured femurs (Fig. 1f) which continues up to the third month (Fig. 1g). From this 
implantation time, the outline gradually becomes diffuse and is more difficult to be delimited. 
With regard to gas pockets, the maximum volume of gas is observed after 1 month of 
implantation (Figures 1a and 1f). In the group of rats with fractured femur (groups 3 and 4) gas 
is less abundant and is mainly located at the fracture site and extending beyond its limits into the 
surrounding soft tissues, and it is also located at the metaphysis (Fig. 1a). From the third month 
of implantation (Fig. 1b) the amount of gas decreases significantly, with only some bubbles 
remaining in the vicinity of the fracture site. In the subsequent implantation times the gas has 
almost completely disappeared. In the groups of rats of un-fractured femurs (groups 1 and 2), a 
large amount of gas appears after one month of implantation located at the metaphysis and 
around the implant (Fig. 1f). This gas is barely perceptible after five months (Fig. 1h), but 
reappears in the ninth month (Fig. 1i) before finally disappearing completely (Fig. 1j).  
In the rats with fractured femur, bone healing occurred in 100% of animals and the bone callus 
appeared in the third month (Fig. 1b), being the fracture completely healed by the fifth month 
(Fig. 1c). There were no cases of non-union. The bone remodelling capacity is high, as can be 
seen in the tomography images for 9 and 13 months of implantation (Fig.1d and 1e), where 
there is no difference between the rat femurs with previous fracture and those without fracture.  
Table 1 shows the quantitative evolution of the gas volume of uncoated AZ31 alloy for rats with 
fractured femur and un-fractured femur measured from the overlapping of tomography images. 
 
 
 Time 
(months) 
Fractured Femur  
 Gas volume (mm
3
) 
Mean ± SD 
 Un-fractured 
Femur  
 Gas volume (mm
3
) 
Mean ± SD 
1 12.11 ± 6.43 19.09 ± 8.21 
3 6.75 ± 3.91  17.77 ± 8.80 
4 1.32 ± 0.68 6.02 ± 1.07 
8 1.29 ± 1.24 4.31 ± 4.59 
9 1.07 ± 1.20 3.18 ±4.26 
10 0.96 ± 1.21 4.92 ± 4.90 
12 0.23 ± 0.42 1.56 ± 1.07 
13 0.00 ± 0.00 0.21± 0.20 
 
Table 1. Evolution of gas volume released from the biodegradation of uncoated AZ31 alloy 
implant versus implantation time in Wistar rats with and without fractured femur.  
The volume of gas released is equivalent to the amount of AZ31 biodegraded (in mols). As can 
be seen in table 1, in the group of un-fractured femurs the gas accumulated after one month 
averages 19.09 ± 8.21mm
3
; while in the rats with fractured femur the value is lower, 12.11 ± 
6.43 mm
3
. Between 8 and 10 months of implantation the amount of gas raises in the group of 
animals with un-fractured femurs. The value of 1.32 ± 0.68 mm
3
 is reached in the fourth month 
in the rats with fractured femurs, whereas in the animals with un-fractured femurs, this value is 
reached after 12 months (1.56 ± 1.07 mm
3
). There were not statistically significant differences 
between fractured and un-fractured femur. 
3.1.2. Histological and histomorphometric analysis 
Fig. 2 shows the representative cross section images at different magnifications of the partially 
resorbed AZ31 implants of group 2 (un-fractured femur and without MgF2 coating) after 1 and 
13 months implantation times. 
  
Figure 2. Histological cross-section images of the partially resorbed AZ31 magnesium alloy 
implants after 1 month (a, b) and 13 months (c, d). Samples a), b) and c) were stained with 
Masson's trichrome: green-calcified mature bone tissue; orange-uncalcified osteoid tissue; dark 
red-cell nuclei. Sample d) was stained with haematoxylin enhancing the blue toluidine:  dark, 
almost black-cell nuclei; shades of blue, depending on the degree of maturity of the bone-
intercellular substance. 
Cells and intercellular substance are differentiated depending on the staining used. However, 
implanted material always appears undyed and black, which are easily identified. Implants are 
easily recognized in the initial site of implantation by the new circle of tissue around (as shown 
in Figure 2). Resorbed implant appears as grey colour so the remaining area in black colour is 
measured. 
 After 1 month (Fig. 2a and b) it is possible to see a circular black area identified as the AZ31 
implant and evidence of bone neoformation in the medullary cavity, distinguishing a thick 
trabecula of cortical bone. In the bone trabecula cavities it is possible to see bone marrow of an 
orange coloured dotted appearance. It can also be seen that the implant is partially resorbed at 
 the edges (Fig. 2b). The resorbed area has been occupied by inorganic compounds, Mg oxides 
and hydroxides, corrosion products that surround the surface of the implant. On the other hand, 
a lamina of fibrous tissue is seen separating the original area of bone tissue that surrounds it, 
although no foreign body or inflammatory cells have been found. After 13 months the implant 
is partially resorbed (Fig. 2c and d), being possible to observe breakage of the fibrous tissue 
encapsulation that surrounds the biomaterial. 
Histomorphometric analysis allows us to quantify the real resorption of the implant from the 
remaining implant areas measured on the different cross sections. The information obtained 
from micro CT and histomorphometric analysis is complementary and do not have necessarily 
to follow the same trend. 
Fig. 3 quantifies the implant resorption percentages, which after 1, 9 and 13 months for the 
groups 2 and 4 (uncoated implants) rats with un-fractured and fractured femur, respectively. 
Resorption percentage was calculated considering that the resorbed implant appears as grey 
colour and the implant area not resorbed appears as black colour. The resorption percentage was 
calculated from the difference between the original volume and that remaining. 
Figure 3. Percentage of AZ31 uncoated implant resorption after 1, 9 and 13 months in Wistar 
rats with fractured and un-fractured femurs. 
 Histomorphometric studies reveal that after one month the percentage of resorbed material is 
similar in both groups. The corrosion that occurs does not alter its central structure and takes the 
form of pitting corrosion that starts on its surface. Nevertheless, resorption percentage at long 
implantation times is higher in the group of rats 2 without fractured femur. After 9 months, 
when the fractures have been consolidated, 41.85% of the material has been resorbed and its 
central structure is conserved.   
3.1.3. Effect of MgF2 coating on the biodegradation rate 
The analysis of the effect of MgF2 coating on the biodegradation rate of AZ31 implants, was 
studied in the groups 3 and 4, rats with fractured femur. Images acquired from computed 
tomography show the corroded implant without possible distinction between the remaining 
implant and the corrosion products that has been defined as the total volume of the implant. In 
Figure 4, the total volume of the implant including corrosion products and gas volume in AZ31 
with and without MgF2 coating from 1 to 13 months in Wistar rats with fractured femurs is 
shown. 
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Figure 4. Total volume of the implant and corrosion products, a), and gas volume, b), in AZ31 
with and without MgF2 coating from 1 to 13 months in Wistar rats with fractured femur.  
MgF2 coating seems to have a small influence on the biocorrosion process. The first four 
months of implantation, the modification of the surface slightly reduces the biocorrosion of the 
implant. However, from the fourth month to the end of the in vivo experimentation the trend is 
reversed due to a higher amount of corrosion products which increases the total volume of the 
implant. The evolution of the gas volume over time in coated and uncoated AZ31 implants for 
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 rats with fractured femurs was nearly parallel with small differences between them. There were 
not statistically significant differences between uncoated and coated implants. 
Table 2 shows in statistical quantitative terms the percentage of biodegraded AZ31 implants 
with and without MgF2 coating in Wistar rats with fractured femur after 1, 9 and 13 months of 
implantation.  
AZ31 implant resorption (%) 
Time 
(months) 
MgF2 coated implants Uncoated implants 
 Mean  S.D.  Mean  S.D. 
1  24.52 5.00 26.34 5.31 
9 43.94 7.48  41.85 12.71 
13 53.51 16.82  46.32 15.30 
 
Table 2. Percentage of AZ31 implant resorption, after 1, 9 and 13 months with and without 
MgF2 coating in Wistar rats with fractured femur. S.D: Standard Deviation.  
 
It can be seen that the resorption of the material after 1, 9 and 13 month is not statistically 
significant between the group 3 with MgF2 coated AZ31 implant and the group 4 with uncoated 
AZ31 implants. 
4. Discussion 
A material that is to be used in fracture osteosynthesis must fulfil a number of basic 
requirements: 1) retain its mechanical properties long enough to achieve bone healing, i.e. 
present little degradation between weeks 3 and 16, when the bone callus is forming [25,26]; 2) 
be biocompatible; and 3) allow bone regeneration ad integrum (occurs between 12 and 15 
months) [27-30], which means that during all this time the material must degrade at a controlled 
rate. The final result is an appropriate balance between the bone healing process and 
biodegradation of the material. 
 Previous in vitro and in vivo studies have shown that Mg and its alloys are biocompatible 
materials that do not cause systemic inflammatory reactions or alterations in analytical 
parameters [31-33]. However, the biodegradation process of Mg base temporary materials in 
vivo presents two fundamental problems for use in clinical practice: on the one hand the fast 
corrosion of the material [34-36], which leads to a loss of mechanical properties and, on the 
other hand, the formation of gas associated with the biodegradation process, which can affect 
bone healing [32,33,37].  
4.1. Does the AZ31 corrosion rate allow the implant material to maintain its mechanical 
support long enough for bone healing? 
The in vivo corrosion reaction takes place according to two semi-reactions: 
- Anodic or oxidation: Mg
0
  → Mg 2+ + 2e-  (2) 
- Cathodic or reduction: 2H2O + 2e
- → + 2 OH- + H2 (g)    (3) 
The first semi-reaction starts on the implant surface (with or without surface treatment) right 
from the initial moments of its insertion. It occurs because the surface is bathed in the 
physiological fluid containing water and mineral salts, giving rise to the formation of Mg oxide 
and hydroxide, and probably also the phosphates and carbonates that are deposited on the metal 
surface as detected in in vitro and in vivo test [35,36]. The Mg hydroxides form a protective 
layer, but in a chloride medium, when the chloride ion concentration reaches 30 mmol/L, Mg 
hydroxides are transformed into highly soluble magnesium chlorides [38]. This promotes the 
appearance of pitting on the implant surface. If the chloride concentration in the extracellular 
fluid reaches 150 mmol/L, pitting corrosion becomes severe [38]. Figure 5 shows the deposited 
corrosion products (identified with letter b in Figure 5).  
  
Figure 5. Histological cross-section images of implanted AZ31 magnesium alloy after 9 months 
in Wistar rats. Letters in the images: a-pitting corrosion b-corrosion products and c-new bone. 
These Mg oxides and hydroxides promote the accumulation of calcium phosphate and therefore 
the formation of new bone around the implant (Figure 5c) [34]. The accumulated oxides and 
hydroxides have a similar atomic number to Mg, and for this reason cannot be distinguished 
from the pin in computed tomography. As a result it was decided to quantify the biodegradation 
process by measuring the cathodic or reduction reaction (3), i.e. gas pockets by processing the 
images taken from tomography. The organism is able to absorb the gas produced and expel it by 
diffusion, but if the hydrogen formation rate is very high the gas excess is accumulated as 
bubbles around the implant or fracture site (Figure 1a) [35,37]. In groups 1 and 2 (un-fractured 
femur) the corrosion products from the biodegradation process (equation (1)) remain on the 
implant surface, to a certain extent protecting the surface from the corrosion process. As the 
 corrosion products become more voluminous and porous, oxygen and water have access to the 
metallic surface, reactivating the corrosion process. For this reason gas reappears in the 
metaphysis in the un-fractured femur of the rats, whereas this oscillation does not take place in 
the rats with fractured femur (Table 1). It can be seen that gas production is much greater in the 
first month and subsequently drops until it almost disappears. However, in the rats with 
fractured femur less gas is quantified than in those un-fractured femur, and the oscillation in gas 
production does not occur. All of these differences may be attributed to the fact that only 
intramedullary gas and peri-fracture gas appears in the image quantification. The gas diffused 
through the soft tissues in close contact with the material is not measured, i.e. it is formed but 
not in enough amount to be accumulated in pockets. In other words, in a richly vascularised 
environment gas does not accumulate but dissolves and is eliminated by normal biological 
procedures [39,40]. The gas is not only H2 as appears in equations (1) and (3) [41]. As early as 
1900, Payr [42] hypothesised that the accumulated gas was a mixture of oxygen and hydrogen. 
Subsequently McBride shows that there was carbon dioxide (5.6%), oxygen (6.5%), hydrogen 
(7.3%) and nitrogen (80.6%) [43]. Recent studies indicate not only the presence of hydrogen gas 
but a mixture of gases [39, 44]. 
Some authors discuss whether gas formation at the fracture site may delay or alter callus 
formation and therefore fracture healing [45-48]. Kraus [5] argues that callus formation in the 
medial cortex is greater due to the accumulation of gas in this cortex which is the area of least 
resistance. However, in a relatively stable synthesised femur fracture the fracture callus will 
always be hypertrophic and will always be greater in the medial cortex, because it supports 
compression forces while the outer cortex supports tension forces. According to Roux-Wolff's 
law [49], bone formation is guided by mechanical forces and bone has the capacity to adapt its 
architecture to external loads. More recently, a mathematical simulation carried out on the bone 
structure and its biological adaptation to the mechanical load to which it is subjected, 
demonstrated and validated Wolff's studies by microCT and microFEA (finite element 
analysis)[50]. In the present study, pseudoarthrosis does not occur in any case and the shape of 
 the bone callus is homogenous for all the groups. That is why there are not clinical secondary 
reactions due to the gas. 
It can be concluded that bone healing occurred in 100% of the study animals. The bone callus 
was seen in the third month (Fig. 1b) and the fracture was considered to be completely 
consolidated in the fifth month (Fig. 1c).  
4.2. Biocompatibility of AZ31 alloy  
Throughout the implantation time (1 to 13 months) of the AZ31 implant, coated and uncoated, 
the implanted material did not cause clinical alterations such as reddening or the appearance of 
obvious gas bubbles or deaths due to embolism. The animals subjected to a fracture of the femur 
could not be immobilised and showed reduced mobility for the first 3 weeks after surgery, but 
their habitual behaviour was not altered. 
In the histological studies after 1 month of implantation it has been seen that there is neither 
reaction to the foreign body nor any inflammatory reaction (Figs. 2a and 2b). The insertion of 
any material in an intramedullary cavity generally leads to a process of relative osteolysis or 
bone resorption which is considered normal. With the AZ31 alloy no such osteolysis has taken 
place (Figs. 2c and 2d) and the images show osteoblast activity by the presence of bone 
formation. Osteoclasts were not appreciated. After this first month a thin fibrous layer is seen 
surrounding the material, and based on polarised light studies this layer corresponds to bone 
tissue immature (Fig. 2b). After 13 months the studies confirm that the material is completely 
surrounded by a layer of mature bone tissue. This new bone is firmly adhered to the implant 
surface. This represents a direct index of the implant's good biocompatibility and its 
osteoproliferative capacity. These results are in accordance with those obtained by other authors 
[21,38,51-53]. No histological differences are seen between the reactions that take place on 
MgF2 coated and uncoated surfaces.  
Histomorphometric studies reveal that after 9 months, 41.85% of the material has been 
resorbed. This resorption of more than 40% after 9 months means that this material cannot be 
 described as suitable for the osteosynthesis of bones subjected to great loads, due to the possible 
loss of mechanical properties [54]. 
4.3. Effect of MgF2 on the biodegradation rate of AZ31 implants  
The magnesium fluoride coating, which in in vitro studies was seen to be highly efficient at 
reducing the corrosion rate of AZ31 alloy [55, 56], has not reduced corrosion of the implant at 
long implantation times in the present study. Although the initial biodegradation (1 month) is 
similar in the implants with and without surface treatment, the biodegradation rate after 13 
months is greater in the case of the implants with a magnesium fluoride coating (Table 2). The 
volume of corroded implants of coated AZ31 implants follow the same trend as Thoman’s 
studies about in vivo degradation of MgCa0.8 implants [57], who found that “after 6 months the 
volume of the coated implants was 13% higher than the volume of the uncoated pins”. In 
general, the protective coating is compact and uniform, however over time physiological fluids 
pass through defects such as pores and cracks until arriving AZ31 surface, promoting nuclei for 
corrosion attack. Gu describes this mechanism in AZ31 alloy in vitro [36]. According to Wang 
corrosion accelerates if the coating is locally destroyed [7]. Studies performed with Scanning 
Kelvin Probe revealed [58] that the difference of potential established between areas protected 
by the coated surface (790 mV) and uncoated areas (360 mV) gives rise to galvanic corrosion 
couples which accelerate corrosion. It should also be remembered that the pH in areas adjacent 
to where corrosion is taking place can reach values of 9, and at these pH values the magnesium 
fluoride coating is not stable and is easy to dissolve. 
Once again the widely debated question arises as to how far the in vivo situation of magnesium 
is reproduced in vitro tests, given that there are many physiological factors in vivo that make in 
vitro studies a poor comparison [32]. In vitro studies cannot take into account variables such as 
electrochemical plugging by proteins, diffusion through the membranes formed by the implant, 
or localised pH alterations [59]. A variable that has been little studied is the thickness of the 
electrolyte bathing the implant. Montoya et al. conclude that biodegradation differs according to 
 the electrolyte thickness at the implant site [60]. These authors identify by means of a 
mathematical model the variables that affect the biodegradation of magnesium such as the type 
of material (AZ31, cast Mg and powder metallurgical Mg) thickness of the electrolyte 
surrounding the implant, and density of the particles embedded in it.  
The surface modification of AZ31 with the magnesium fluoride coating is not justified in in vivo 
experimentation, so it would not be necessary to apply it to protect the implant and this would 
also avoid the potential problems related with fluoride ions.  
4.4. Biodegradation and bone restitution 
Bone regeneration ad integrum means that throughout the time the material presents 
degradation at a controlled rate until its complete disappearance.  
In this study complete degradation of the material was not reached, and so its degradation 
kinetics beyond 13 months is not known. With regard to complete bone restitution, the 
computed tomography images (Figs. 1i and 1j) show the bone remodelling capacity which 
allowed the fractured femurs to have a similar morphology to un-fractured femurs after 9 to 13 
months. The balance that is sought between bone healing and biodegradation of the material 
seems to be achieved without difficulty for the studied group of rats with AZ31 alloy [2, 61].  
In summary this animal experimentation study has shown that AZ31 alloy has real potential to 
be used as an osteosynthesis material in fractures. It offers the main advantage of its 
degradation once the healing process has finished, thus avoiding the need to remove the 
material.  
5. Conclusions 
- The fracture is healed in 100% of the animals, and AZ31 alloy maintains its mechanical 
integrity throughout the healing process. The gas produced in the biodegradation process of 
 AZ31 is exchanged and dissipates quickly, not altering the formation or the morphology of the 
bone callus.  
- AZ31 alloy is a biocompatible material with osteoproliferative properties. Surface 
modification with MgF2 is also well tolerated by the organism. 
- There is not statistically significant differences in the resorption process between coated and 
uncoated AZ31 implants inserted in fractured femurs after 1, 9 and 13 month. 
- There is a balance between the biodegradation of AZ31 and bone healing which allows the use 
of AZ31 to be proposed as an osteosynthesis material, although its resorption seems to make it 
more advisable for bones not subjected to mechanical loads. 
Acknowledgements 
The authors are grateful to MINECO, Spain, for financial support of projects MAT 2008-06719-
C03-01-03 and MAT 2011-29152-C02-01. The authors would like to thank the technical 
assistance to R. Fernandez, M. Delgado, and L. Garcia from Instituto Pluridisciplinar (U. 
Complutense of Madrid). Also to thank N. Malpica from U. Rey Juan Carlos of Madrid for the 
support in the ITK-SNAP application.  
References 
[1] C. Hampp, N. Angrisani, J. Reifenrath, D. Bormann, J.-M. Seitz, A. Meyer-
Lindenberg, Evaluation of the biocompatibility of two magnesium alloys as 
degradable implant materials in comparison to titanium as non-resorbable material 
in the rabbit, Materials Science & Engineering C-Materials for Biological 
Applications, 33 (2013) 317-326. 
[2] H. Windhagen, K. Radtke, A. Weizbauer, J. Diekmann, Y. Noll, U. Kreimeyer, R. 
Schavan, C. Stukenborg-Colsman, H. Waizy, Biodegradable magnesium-based 
screw clinically equivalent to titanium screw in hallux valgus surgery: short term 
results of the first prospective, randomized, controlled clinical pilot study, 
Biomedical Engineering Online, 12 (2013). 
[3] J. Walker, S. Shadanbaz, T.B.F. Woodfield, M.P. Staiger, G.J. Dias, Magnesium 
biomaterials for orthopedic application: A review from a biological perspective, 
Journal of Biomedical Materials Research Part B-Applied Biomaterials, 102 
(2014) 1316-1331. 
[4] L.E. Claes, Mechanical characterization of biodegradable implants, Clinical 
materials, 10 (1992) 41-46. 
 [5] T. Kraus, S.F. Fischerauer, A.C. Hanzi, P.J. Uggowitzer, J.F. Loffler, A.M. 
Weinberg, Magnesium alloys for temporary implants in osteosynthesis: in vivo 
studies of their degradation and interaction with bone, Acta Biomater, 8 (2012) 
1230-1238. 
[6] N.T. Kirkland, Magnesium biomaterials: past, present and future, Corrosion 
Engineering Science and Technology, 47 (2012) 322-328. 
[7]  J. Wang, J. Tang, P. Zhang, Y. Li, J. Wang, Y. Lai, L. Qin, Surface modification 
of magnesium alloys developed for bioabsorbable orthopedic implants: A general 
review, Journal of Biomedical Materials Research Part B-Applied Biomaterials, 
100B (2012) 1691-1701. 
[8] S. Hirano, K.T. Suzuki, Exposure, metabolism, and toxicity of rare earths and 
related compounds, Environmental Health Perspectives, 104 (1996) 85-95. 
[9] C.K. Yuen, W.Y. Ip, Theoretical risk assessment of magnesium alloys as 
degradable biomedical implants, Acta Biomaterialia, 6 (2010) 1808-1812. 
[10] S. Gogolewski, Bioresorbable polymers in trauma and bone surgery, Injury, 31 
Suppl 4 (2000) 28-32. 
[11] W.-D. Mueller, M.L. Nascimento, M. Fernandez Lorenzo de Mele, Critical 
discussion of the results from different corrosion studies of Mg and Mg alloys for 
biomaterial applications, Acta Biomaterialia, 6 (2010) 1749-1755. 
[12] J.A. del Valle, O.A. Ruano, Superplasticity in a magnesium alloy prepared with 
bimodal grain size distributions developed by dynamic recrystallisation, Materials 
Letters, 62 (2008) 3391-3394. 
[13] J.A. del Valle, F. Carreno, O.A. Ruano, Influence of texture and grain size on 
work hardening and ductility in magnesium-based alloys processed by ECAP and 
rolling, Acta Materialia, 54 (2006) 4247-4259. 
[14] M. Alvarez-Lopez, M. Dolores Pereda, J.A. del Valle, M. Fernandez-Lorenzo, 
M.C. Garcia-Alonso, O.A. Ruano, M.L. Escudero, Corrosion behaviour of AZ31 
magnesium alloy with different grain sizes in simulated biological fluids, Acta 
Biomaterialia, 6 (2010) 1763-1771. 
[15] L. Choudhary, R.K.S. Raman, Magnesium alloys as body implants: Fracture 
mechanism under dynamic and static loadings in a physiological environment, 
Acta Biomaterialia, 8 (2012) 916-923. 
[16] H. Wang, S. Guan, Y. Wang, H. Liu, H. Wang, L. Wang, C. Ren, S. Zhu, K. 
Chen, In vivo degradation behavior of Ca-deficient hydroxyapatite coated Mg-Zn-
Ca alloy for bone implant application, Colloids and Surfaces B-Biointerfaces, 88 
(2011) 254-259. 
[17] D. Mushahary, C. Wen, J.M. Kumar, J. Lin, N. Harishankar, P. Hodgson, G. 
Pande, Y. Li, Collagen type-I leads to in vivo matrix mineralization and 
secondary stabilization of Mg-Zr-Ca alloy implants, Colloids and surfaces. B, 
Biointerfaces, 122 (2014) 719-728. 
[18] Y.K. Pan, C.Z. Chen, D.G. Wang, T.G. Zhao, Improvement of corrosion and 
biological properties of microarc oxidized coatings on Mg-Zn-Zr alloy by 
optimizing negative power density parameters, Colloids and Surfaces B-
Biointerfaces, 113 (2014) 421-428. 
[19] A. Abdal-hay, N.A.M. Barakat, J.K. Lim, Hydroxyapatite-doped poly(lactic acid) 
porous film coating for enhanced bioactivity and corrosion behavior of AZ31 Mg 
alloy for orthopedic applications, Ceramics International, 39 (2013) 183-195. 
[20] M. Carboneras, L.S. Hernandez, J.A. del Valle, M.C. Garcia-Alonso, M.L. 
Escudero, Corrosion protection of different environmentally friendly coatings on 
 powder metallurgy magnesium, Journal of Alloys and Compounds, 496 (2010) 
442-448. 
[21] C.A. Grillo, F. Alvarez, M.A.F. Lorenzo de Mele, Biological effects of 
magnesium particles degradation on UMR-106 cell line: Influence of fluoride 
treatments, Colloids and Surfaces B-Biointerfaces, 88 (2011) 471-476. 
[22] S.F. Fischerauer, T. Kraus, X. Wu, S. Tangl, E. Sorantin, A.C. Hanzi, J.F. Loffler, 
P.J. Uggowitzer, A.M. Weinberg, In vivo degradation performance of micro-arc-
oxidized magnesium implants: a micro-CT study in rats, Acta Biomater, 9 (2013) 
5411-5420. 
 [23] P.A. Yushkevich, J. Piven, H.C. Hazlett, R.G. Smith, S. Ho, J.C. Gee, G. Gerig, 
User-guided 3D active contour segmentation of anatomical structures: 
Significantly improved efficiency and reliability, Neuroimage, 31 (2006) 1116-
1128. 
 [24] K. Donath, G. Breuner, A method for the study of undecalcified bones and teeth 
with attached soft-tissues - the sage-schliff (sawing and grinding) technique, 
Journal of Oral Pathology & Medicine, 11 (1982) 318-326. 
[25] D.F. Williams, On the mechanisms of biocompatibility, Biomaterials, 29 (2008) 
2941–2953. 
[26] H. Waizy, J.-M. Seitz, J. Reifenrath, A. Weizbauer, F.-W. Bach, A. Meyer-
Lindenberg, B. Denkena, H. Windhagen, Biodegradable magnesium implants for 
orthopedic applications, Journal of Materials Science, 48 (2013) 39-50. 
[27] C. Janning, E. Willbold, C. Vogt, J. Nellesen, A. Meyer-Lindenberg, H. 
Windhagen, F. Thorey, F. Witte, Magnesium hydroxide temporarily enhancing 
osteoblast activity and decreasing the osteoclast number in peri-implant bone 
remodelling, Acta Biomaterialia, 6 (2010) 1861-1868. 
[28] R. Schmidhammer, S. Zandieh, R. Mittermayr, L.E. Pelinka, M. Leixnering, R. 
Hopf, A. Kroepfl, H. Redl, Assessment of bone union/nonunion in an 
experimental model using microcomputed technology, Journal of Trauma-Injury 
Infection and Critical Care, 61 (2006) 199-205. 
[29] D.W. Buck, II, G.A. Dumanian, Bone Biology and Physiology: Part I. The 
Fundamentals, Plastic and Reconstructive Surgery, 129 (2012) 1314-1320. 
[30] D.W. Buck, II, G.A. Dumanian, Bone Biology and Physiology: Part II. Clinical 
Correlates, Plastic and Reconstructive Surgery, 129 (2012) 950-956. 
[31] K. Yu, L. Chen, J. Zhao, R. Wang, Y. Dai, Q. Huang, In vivo biocompatibility 
and biodegradation of a Mg-15%Ca-3(PO4)(2) composite as an implant material, 
Materials Letters, 98 (2013) 22-25. 
[32] D.-T. Chou, D. Hong, P. Saha, J. Ferrero, B. Lee, Z. Tan, Z. Dong, P.N. Kumta, 
In vitro and in vivo corrosion, cytocompatibility and mechanical properties of 
biodegradable Mg-Y-Ca-Zr alloys as implant materials, Acta Biomaterialia, 9 
(2013) 8518-8533. 
[33] R.-G. Guan, I. Johnson, T. Cui, T. Zhao, Z.-Y. Zhao, X. Li, H. Liu, 
Electrodeposition of hydroxyapatite coating on Mg-4.0Zn-1.0Ca-0.6Zr alloy and 
in vitro evaluation of degradation, hemolysis, and cytotoxicity, Journal of 
Biomedical Materials Research Part A, 100A (2012) 999-1015. 
[34] L. Xu, E. Zhang, D. Yin, S. Zeng, K. Yang, In vitro corrosion behaviour of Mg 
alloys in a phosphate buffered solution for bone implant application, Journal of 
Materials Science-Materials in Medicine, 19 (2008) 1017-1025. 
[35] F. Witte, J. Fischer, J. Nellesen, H.A. Crostack, V. Kaese, A. Pisch, F. Beckmann, 
H. Windhagen, In vitro and in vivo corrosion measurements of magnesium alloys, 
Biomaterials, 27 (2006) 1013-1018. 
 [36] X. Gu, Y. Zheng, Y. Cheng, S. Zhong, T. Xi, In vitro corrosion and 
biocompatibility of binary magnesium alloys, Biomaterials, 30 (2009) 484-498. 
[37] M.P. Staiger, A.M. Pietak, J. Huadmai, G. Dias, Magnesium and its alloys as 
orthopedic biomaterials: A review, Biomaterials, 27 (2006) 1728-1734. 
[38] F. Witte, N. Hort, C. Vogt, S. Cohen, K.U. Kainer, R. Willumeit, F. Feyerabend, 
Degradable biomaterials based on magnesium corrosion, Current Opinion in Solid 
State & Materials Science, 12 (2008) 63-72. 
[39] F. Witte, The history of biodegradable magnesium implants: A review, Acta 
Biomaterialia, 6 (2010) 1680-1692. 
[40] W. Wu, S. Chen, D. Gastaldi, L. Petrini, D. Mantovani, K. Yang, L. Tan, F. 
Migliavacca, Experimental data confirm numerical modeling of the degradation 
process of magnesium alloys stents, Acta Biomaterialia, 9 (2013) 8730-8739. 
[41] D. Mantovani, F. Witte, The Thermec'2009 Biodegradable Metals, Acta 
Biomaterialia, 6 (2010) 1679-1679. 
[42] E. Payr, Beitrage zur Technik der Blutgefass und Nervennaht nebst Mittheilungen 
uber die Verwendung eines resorbirbaren Metalles in der Chirurgie., Arch Klin 
Chir, 62 (1900) 67–93. 
[43] E.D. McBride, Magnesium screw and nail transfixion in fractures, South. Madical 
J. , 31 (1938) 508–515. 
[44] J. Kuhlmann, I. Bartsch, E. Willbold, S. Schuchardt, O. Holz, N. Hort, D. 
Hoeche, W.R. Heineman, F. Witte, Fast escape of hydrogen from gas cavities 
around corroding magnesium implants, Acta Biomaterialia, 9 (2013) 8714-8721. 
[45] L.C. Gerstenfeld, Y.M. Alkhiary, E.A. Krall, F.H. Nicholls, S.N. Stapleton, J.L. 
Fitch, M. Bauer, R. Kayal, D.T. Graves, K.J. Jepsen, T.A. Einhorn, Three-
dimensional reconstruction of fracture callus morphogenesis, Journal of 
Histochemistry & Cytochemistry, 54 (2006) 1215-1228. 
[46] J.M. Garcia-Aznar, J.H. Kuiper, M.J. Gomez-Benito, M. Doblare, J.B. 
Richardson, Computational simulation of fracture healing: Influence of 
interfragmentary movement on the callus growth, Journal of Biomechanics, 40 
(2007) 1467-1476. 
[47] F.T. Beil, F. Barvencik, M. Gebauer, B. Beil, P. Pogoda, J.M. Rueger, A. 
Ignatius, T. Schinke, M. Amling, Effects of Increased Bone Formation on 
Fracture Healing in Mice, Journal of Trauma-Injury Infection and Critical Care, 
70 (2011) 857-862. 
[48] C. Kratzel, C. Bergmann, G. Duda, S. Greiner, G. Schmidmaier, B. Wildemann, 
Characterization of a rat osteotomy model with impaired healing, Bmc 
Musculoskeletal Disorders, 9 (2008). 
[49] J. Wolff, Das Gesetz der Transformation der Knochen., Berlin, 1892. 
[50] R. Huiskes, If bone is the answer, then what is the question?, Journal of Anatomy, 
197 (2000) 145-156. 
[51] E. Willbold, F. Witte, Histology and research at the hard tissue-implant interface 
using Technovit 9100 New embedding technique, Acta Biomaterialia, 6 (2010) 
4447-4455. 
[52] C. Castellani, R.A. Lindtner, P. Hausbrandt, E. Tschegg, S.E. Stanzl-Tschegg, G. 
Zanoni, S. Beck, A.M. Weinberg, Bone-implant interface strength and 
osseointegration: Biodegradable magnesium alloy versus standard titanium 
control, Acta Biomater, 7 (2011) 432-440. 
[53] N. Erdmann, N. Angrisani, J. Reifenrath, A. Lucas, F. Thorey, D. Bormann, A. 
Meyer-Lindenberg, Biomechanical testing and degradation analysis of MgCa0.8 
 alloy screws: A comparative in vivo study in rabbits, Acta Biomaterialia, 7 (2011) 
1421-1428. 
[54] J. Kubasek, D. Vojtech, J. Lipov, T. Ruml, Structure, mechanical properties, 
corrosion behavior and cytotoxicity of biodegradable Mg-X (X = Sn, Ga, In) 
alloys, Materials Science & Engineering C-Materials for Biological Applications, 
33 (2013) 2421-2432. 
[55] M. Carboneras, M.C. Garcia-Alonso, M.L. Escudero, Biodegradation kinetics of 
modified magnesium-based materials in cell culture medium, Corrosion Science, 
53 (2011) 1433-1439. 
[56] R.M. Lozano, B.T. Perez-Maceda, M. Carboneras, E. Onofre-Bustamante, M.C. 
Garcia-Alonso, M.L. Escudero, Response of MC3T3-E1 osteoblasts, L929 
fibroblasts, and J774 macrophages to fluoride surface-modified AZ31 magnesium 
alloy, Journal of biomedical materials research. Part A, 101 (2013) 2753-2762. 
 [57] M. Thomann, C. Krause, N. Angrisani, D. Bormann, T. Hassel, H. Windhagen, 
A. Meyer-Lindenberg, Influence of a magnesium-fluoride coating of magnesium-
based implants (MgCa0.8) on degradation in a rabbit model, Journal of 
Biomedical Materials Research Part A, 93A (2010) 1609-1619. 
[58] M. Carboneras, C. Iglesias, B.T. Perez-Maceda, J.A. del Valle, M.C. Garcia-
Alonso, M.A. Alobera, C. Clemente, J.C. Rubio, M.L. Escudero, R.M. Lozano, 
Corrosion behaviour and in vitro/in vivo biocompatibility of surface-modified 
AZ31 alloy, Revista De Metalurgia, 47 (2011) 212-223. 
[59] E. Willbold, A.A. Kaya, R.A. Kaya, F. Beckmann, F. Witte, Corrosion of 
magnesium alloy AZ31 screws is dependent on the implantation site, Materials 
Science and Engineering B-Advanced Functional Solid-State Materials, 176 
(2011) 1835-1840. 
[60] R. Montoya, C. Iglesias, M.L. Escudero, M.C. Garcia-Alonso, Modeling in vivo 
corrosion of AZ31 as temporary biodegradable implants. Experimental validation 
in rats, Materials Science & Engineering C-Materials for Biological Applications, 
41 (2014) 127-133. 
[61] R.B. Bell, C.S. Kindsfater, The use of biodegradable plates and screws to 
stabilize facial fractures, Journal of Oral and Maxillofacial Surgery, 64 (2006) 31-
39. 
 
 
